← Back to Search

Behavioural Intervention

SynPhNe Therapy for Stroke Recovery

N/A
Waitlist Available
Led By Paolo Bonato, PhD
Research Sponsored by Spaulding Rehabilitation Hospital
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Moderate upper-extremity hemiparesis (initial score on the Upper Extremity Fugl-Meyer Assessment between 21 and 55 out of 66)
Ability to extend at least 2 fingers in the affected hand 10 degrees at any joint with pain-free passive range of motion at least 50% in all joints below the elbow.
Must not have
Poor sitting balance (as assessed with the Berg Balance Test)
Previous diagnosis of neurological diseases other than Stroke
Timeline
Screening 3 weeks
Treatment Varies
Follow Up changes from baseline scores at baseline, at 7 weeks and at one month follow-up
Awards & highlights

Summary

This trial is testing a new device that may help improve hand function for people who have had a stroke.

Who is the study for?
This trial is for chronic stroke survivors who had a stroke at least 6 months ago and have moderate hand weakness. They must be able to move two fingers slightly and follow instructions. People with severe cognitive issues, current therapy, recent Botox in the arm, poor balance, severe communication problems, high muscle tone or other major health issues can't join.
What is being tested?
The study tests the SynPhNe platform—a device for home-based hand function training—against standard care alone. It aims to see if using SynPhNe along with some conventional therapy sessions is better at improving motor skills in the affected hand of stroke patients.
What are the potential side effects?
While specific side effects are not listed for this trial, typical risks may include discomfort from wearing the device or fatigue from exercises. The study will monitor participants closely to ensure safety during use.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I have moderate weakness in my arm.
Select...
I can move 2 fingers in my hand and my elbow without much pain.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I have trouble sitting up straight without support.
Select...
I have been diagnosed with a neurological condition, but it's not a stroke.
Select...
My stroke-affected arm has other health issues.
Select...
I cannot provide or give access to brain imaging of my stroke.
Select...
I haven't had Botox in my arm in the last 3 months and don't plan to until the study ends.
Select...
I have had a seizure or been diagnosed with a seizure disorder in the last 6 months.
Select...
My doctor expects I have less than a year to live due to my illness.
Select...
I experience severe pain in my arm affected by stroke.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~changes from baseline scores at baseline, at 7 weeks and at one month follow-up
This trial's timeline: 3 weeks for screening, Varies for treatment, and changes from baseline scores at baseline, at 7 weeks and at one month follow-up for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Box and Block test
Fugl-Meyer Upper Extremity
Wolf Motor Function Test (Upper Extremity)
Secondary study objectives
EQ5D questionnaire
Jamar dynamometer
Modified Ashworth Scale
+3 more
Other study objectives
Device satisfaction feedback questionnaire (only for intervention group)
Goniometry - Active Range of Motion
Manual Muscle Testing (Kendall)
+3 more

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: SynPhNe therapyExperimental Treatment1 Intervention
Subjects will be asked to participate in a program of 18 upper-extremity rehabilitation sessions of 60 minutes with SynPhNe platform, over 6 weeks. The sessions will emphasize on the wrist and fingers movements, including functional activities. During week the two first weeks, 6 sessions will be done under therapist supervision at the Motion Analysis Laboratory at Spaulding Rehabilitation Hospital. Over the next 4 to 5 weeks, 10 sessions following exercises prompted by the SynPhNe system will be done unsupervised at home (or under limited supervision at the hospital), 2 sessions will be done at Spaulding Rehabilitation Hospital to review exercises with the SynPhNe system.
Group II: Conventional therapyActive Control1 Intervention
Subjects will be asked to participate in a program of 18 upper-extremity rehabilitation sessions of 60 minutes under therapist supervision over two weeks at the Motion Analysis Laboratory at Spaulding Rehabilitation Hospital. The sessions will emphasize on the wrist and fingers movements, including functional activities. During week the two first weeks, 6 sessions will be done under therapist supervision at the Motion Analysis Laboratory at Spaulding Rehabilitation Hospital. The remaining 10 sessions will be done unsupervised at home, over approximately 4 weeks, and following the therapist home treatment plan. Over that time, 2 visits to Spaulding Rehabilitation will be made to review home treatment plan. Over the course of the study, participants will wear GeneActiv sensors to gather information about upper-extremity usage.

Find a Location

Who is running the clinical trial?

Spaulding Rehabilitation HospitalLead Sponsor
137 Previous Clinical Trials
10,977 Total Patients Enrolled
25 Trials studying Stroke
922 Patients Enrolled for Stroke
Paolo Bonato, PhDPrincipal InvestigatorSpaulding Rehabilitation Hospital
22 Previous Clinical Trials
678 Total Patients Enrolled
10 Trials studying Stroke
283 Patients Enrolled for Stroke

Media Library

SynPhNe platform (Behavioural Intervention) Clinical Trial Eligibility Overview. Trial Name: NCT02896348 — N/A
Stroke Research Study Groups: SynPhNe therapy, Conventional therapy
Stroke Clinical Trial 2023: SynPhNe platform Highlights & Side Effects. Trial Name: NCT02896348 — N/A
SynPhNe platform (Behavioural Intervention) 2023 Treatment Timeline for Medical Study. Trial Name: NCT02896348 — N/A
~7 spots leftby Dec 2024